RT Book, Section
A1 Phillips, Elizabeth J.
A1 Mallal, Simon
A2 Murray, Michael F.
A2 Babyatsky, Mark W.
A2 Giovanni, Monica A.
A2 Alkuraya, Fowzan S.
A2 Stewart, Douglas R.
SR Print(0)
ID 1102698715
T1 Abacavir Pharmacogenomics
T2 Clinical Genomics: Practical Applications in Adult Patient Care
YR 2014
FD 2014
PB McGraw-Hill Education
PP New York, NY
SN 9780071622448
LK accessmedicine.mhmedical.com/content.aspx?aid=1102698715
RD 2024/04/25
AB Disease  summary:Abacavir  is  a  nucleoside  reverse  transcriptase  inhibitor  used  in  combination  therapy  for  the  treatment  of  the  human  immunodeficiency  virus  type  1  (HIV-1)  that  has  been  associated  with  a  hypersensitivity  reaction  in  approximately  8%  of  those  starting  the  drug.Abacavir  hypersensitivity  reaction  is  characterized  by  greater  than  or  equal  to  two  progressive  symptoms  typically  starting  from  the  second  week  of  therapy  (median  9  days)  with  fever,  malaise,  nausea,  vomiting,  diarrhea,  and  later  mild-to-moderate  skin  rash  (present  in  70%  of  patients).Symptoms  of  abacavir  hypersensitivity  resolve  rapidly  with  24  to  72  hours  after  drug  discontinuation.A  previous  clinical  history  compatible  with  abacavir  hypersensitivity  is  a  contraindication  to  future  rechallenge  as  severe  morbidity  and  even  mortality  characterized  by  hypotension  and  shock  has  been  described.